Edgewise Therapeutics announced positive top-line results from the 12-week Phase 2 CIRRUS-HCM trial of EDG-7500, a novel oral drug for obstructive and nonobstructive hypertrophic cardiomyopathy (HCM). The data will be presented at the European Society of Cardiology Congress in August 2026, highlighting the drug's potential to improve heart relaxation and function in symptomatic HCM patients. This trial is part of a multi-part study evaluating safety, efficacy, and dosing of EDG-7500, addressing a significant unmet need in treating this genetic heart disease that affects 1 in 500 people. The presentation will be available on Edgewise's website after the congress.
Analyst BTIG upgraded Medtronic to a Buy rating and raised its price target to $100, citing strong Q1 FY2027 revenue of $9.76 billion driven by broad demand. The company is investing over $700 million in Heart Tech and Robotics, signaling a focus on ...
Regis Corporation reported a strong Q4 2026 with earnings per share of $1.04, far exceeding analyst expectations of $0.17. The company generated $56 million in revenue, slightly down year-over-year but above estimates, supported by a 2.6% sales rise ...
UBS analyst Michael Brown reaffirmed a Buy rating on KKR & Co. Inc., setting a $123 price target, implying a 15% upside. KKR is selling USI Insurance Services to Aon plc for $17 billion, expected to yield $3.3 billion in after-tax proceeds and $2 bil...
Kazia Therapeutics received a Buy rating from analyst firm BTIG, which raised its price target to $40, up from $34, reflecting strong confidence in the company's lead drug, paxalisib. The drug showed a 52% tumor reduction in preclinical colorectal ca...
OpenAI announced that its upcoming AI model, Astra, is the first to exceed its 'Critical' cybersecurity capability threshold, meaning it can autonomously find and exploit previously unknown security vulnerabilities. This marks Astra as the most advan...
